Key Metrics 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Twilight Litaka Pharma Ltd (TWILITAKA)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 506985 NSE: TWILITAKA Pharmaceuticals & Drugs | Small Cap | Twilight Litaka Phar Share Price
BSE Share Price
Not Listed
Not Listed
Twilight Litaka Pharma Ltd (TWILITAKA)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 506985 NSE: TWILITAKA Pharmaceuticals & Drugs | Small Cap | Twilight Litaka Phar Share Price
BSE Share Price
Not Listed
Not Listed
Key Metrics
Valuation Multiples
Market Cap
₹7 Cr.
Current Price
₹0
52-Week Low / High
₹3 / 3
TTM EPS
₹-56.6
TTM Sales
₹31.5 Cr.
Book Value per Share
₹-55.7
P/E Ratio
0.00
Industry PE
54.9
Price to Book (P/B)
-0.05
Price to Sales (P/S)
0.23
EV/EBITDA
-36.67
Dividend Yield
NAN%
Profitability Efficiency
Return on Equity (ROE)
0.00%
Return on Capital Employed (ROCE)
-55.00%
Return on Assets (ROA)
-35.44%
Operating Profit Margin
-28.4%
Net Profit Margin
-445.02%
Gross Profit Margin
-29.7%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
-88.33%
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
17.28%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹-150 Cr.
Equity
₹12.4 Cr.
Face Value
₹5
All Time Low / High
₹0.68 / 203.90
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation ⓘ
| Mar'05 | Mar'06 | Mar'07 | Mar'08 | Mar'09 | Mar'10 | Mar'11 | Mar'12 | Jun'13 | Jun'14 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 15.5% | 30.7% | 30% | 29.4% | 25.3% | 25.7% | 28% | 11.2% | -40.5% | -55.6% | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 69.5 | 154 | 198 | 295 | 370 | 492 | 657 | 730 | 270 | 31.5 | 12 |
| Sales YoY Gr. | - | 122.3% | 27.9% | 49.3% | 25.6% | 32.8% | 33.6% | 11.1% | -63% | -88.3% | - |
| Adj EPS ⓘ | -0.6 | 9.3 | 6.6 | 8.5 | 9.8 | 14.9 | 22.5 | 1.2 | -52.6 | -56.3 | -59.4 |
| YoY Gr. | - | NA | -29.5% | 29.9% | 15.3% | 51.7% | 51.3% | -94.7% | -4517.7% | NA | - |
| BVPS (₹) ⓘ | -1.4 | 8.8 | 13.6 | 20.9 | 30.1 | 43.6 | 64.7 | 71 | 4.2 | -51 | -58 |
| Adj Net Profit ⓘ | -0.5 | 8.9 | 14 | 18.1 | 20.9 | 31.7 | 48 | 3 | -130 | -140 | -147 |
| Cash Flow from Ops. ⓘ | 3.7 | -7.3 | -2.4 | -18.7 | 5.2 | 14.2 | -5.5 | 1.5 | -4.6 | 1.7 | - |
| Debt/CF from Ops. ⓘ | 8.4 | -8 | -28.2 | -6.4 | 31.1 | 13.8 | -47.2 | 199.2 | -53.1 | 182.5 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | -8.4% | -38.9% | -63.7% | -88.3% | ||||
| Adj EPS ⓘ | NA | -241.8% | -235.7% | NA | ||||
| BVPSⓘ | NA | -211.2% | -192.4% | -1303.5% | ||||
| Share Price | - | - | - | - | ||||
Key Financial Parameters ⓘ
| Mar'05 | Mar'06 | Mar'07 | Mar'08 | Mar'09 | Mar'10 | Mar'11 | Mar'12 | Jun'13 | Jun'14 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | -15.5 | 59 | 46.2 | 42.7 | 34.9 | 36.1 | 37.4 | 1.8 | -162.8 | 273.1 | 109 |
| Op. Profit Mgn % ⓘ | 4.1 | 10 | 13.5 | 13 | 13.2 | 13.6 | 14.9 | 9.4 | -12.2 | -27.8 | 15.3 |
| Net Profit Mgn % ⓘ | -0.8 | 5.8 | 7.1 | 6.2 | 5.6 | 6.4 | 7.3 | 0.4 | -48.3 | -443.1 | -1178.7 |
| Debt to Equity ⓘ | -22.7 | 6.9 | 2.3 | 2.7 | 2.5 | 2.1 | 1.9 | 1.7 | 23.4 | -2.4 | - |
| Working Cap Days ⓘ | 133 | 115 | 159 | 168 | 193 | 183 | 180 | 203 | 422 | 3,261 | 2,538 |
| Cash Conv. Cycle ⓘ | 48 | 67 | 109 | 123 | 148 | 146 | 142 | 164 | 353 | 2,725 | -2,350 |
Valuation of Twilight Litaka Phar - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 98.08 | 91.37 | 72.58 | 72.58 | 4.85 | 4.85 | 4.85 | 4.85 | 4.85 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'10 | Mar'11 | Mar'12 | Jun'13 | Jun'14 |
|---|---|---|---|---|---|
| Sales | 491.96 | 670.83 | 732.56 | 338.39 | 31.50 |
| Operating Expenses ⓘ + | 424.88 | 572.30 | 665.69 | 384.08 | 40.46 |
| Operating Profit ⓘ | 67.08 | 98.53 | 66.87 | -45.68 | -8.95 |
| Operating Profit Margin (%) | 13.6% | 14.7% | 9.1% | -13.5% | -28.4% |
| Other Income ⓘ + | 2.68 | 3.27 | 1.11 | 0.19 | 0 |
| Interest ⓘ | 26.15 | 32.18 | 46.70 | 0.97 | 0.41 |
| Depreciation ⓘ | 3.05 | 3.98 | 5.62 | 7 | 5.39 |
| Profit Before Tax ⓘ | 40.55 | 65.63 | 0.22 | -171.01 | -140.20 |
| Tax ⓘ | 7.93 | 14.38 | 1.17 | -0.06 | 0 |
| Profit After Tax | 32.63 | 51.25 | -0.95 | -170.95 | -140.20 |
| PAT Margin (%) | 6.6% | 7.6% | -0.1% | -50.5% | -445.0% |
| Adjusted EPS (₹) | 15.3 | 24.1 | -0.4 | -69.0 | -56.6 |
| Dividend Payout Ratio (%) | 9.80% | 6.20% | 0% | 0% | 0% |
| PARTICULARS | Mar'10 | Mar'11 | Mar'12 | Jun'13 | Jun'14 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 98.48 | 146.25 | 179.60 | 8.26 | -132.30 | ||||||
| Debt + | 195.19 | 256.29 | 294.03 | 282.74 | 277.33 | ||||||
| Minority Interest | 0 | 0 | 0 | 0 | 0 | ||||||
| Trade Payables | 34.75 | 44.02 | 34.68 | 32.04 | 30.11 | ||||||
| Others Liabilities ⓘ | 31.61 | 53.56 | 59.26 | 136.91 | 156.21 | ||||||
| Total Liabilities ⓘ | 360.04 | 500.12 | 567.58 | 459.95 | 331.35 | ||||||
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 67.37 | 91.44 | 104.25 | 96.81 | 91.42 | ||||||
| CWIP ⓘ | 9.83 | 18.64 | 18.64 | 11.23 | 11.23 | ||||||
| Investments ⓘ | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | ||||||
| Inventories | 69.04 | 88.42 | 80.63 | 55.07 | 4.07 | ||||||
| Trade Receivables | 179.10 | 265.90 | 327.57 | 264.12 | 208.95 | ||||||
| Cash Equivalents | 5.96 | 2.93 | 1.82 | 0.42 | 0.93 | ||||||
| Others Assets ⓘ | 28.70 | 32.74 | 34.62 | 32.26 | 14.71 | ||||||
| Total Assets ⓘ | 360.04 | 500.12 | 567.58 | 459.95 | 331.35 | ||||||
| PARTICULARS | Mar'10 | Mar'11 | Mar'12 | Jun'13 | Jun'14 |
|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 14.17 | -7.72 | 3.86 | -5.46 | 1.52 |
| Cash Flow From Investing Activity ⓘ + | -29.57 | -25.61 | -18.89 | 0.08 | -0.36 |
| Cash Flow From Financing Activity ⓘ + | 17.06 | 30.27 | 13.92 | 3.99 | -0.66 |
| Net Cash Flow ⓘ | 1.66 | -3.06 | -1.10 | -1.40 | 0.50 |
| PARTICULARS | Mar'10 | Mar'11 | Mar'12 | Jun'13 | Jun'14 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 35.13 | 44.08 | -0.6 | -195.03 | N/A | |||||
| ROCE (%) | 22.57 | 27.39 | 10.32 | -41.74 | N/A | |||||
| Asset Turnover Ratio | 1.37 | 1.57 | 1.38 | 0.66 | 0.08 | |||||
| PAT to CFO Conversion(x) | 0.43 | -0.15 | N/A | N/A | N/A | |||||
| Working Capital Days | ||||||||||
| Receivable Days | 132.50 | 120.40 | 147.40 | 319.10 | 2,740.40 | |||||
| Inventory Days | 51.10 | 42.60 | 42 | 73.20 | 342.60 | |||||
| Payable Days | 22 | 23.40 | 25.60 | 41 | 570 | |||||
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Twilight Litaka Pharma Ltd FAQs
The current trading price of Twilight Litaka Phar on 01-Jan-1970 05:30 is ₹0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Twilight Litaka Phar stood at ₹7.14 Cr
The latest P/E ratio of Twilight Litaka Phar as of 31-Dec-1969 is 0.00.
The latest P/B ratio of Twilight Litaka Phar as of 31-Dec-1969 is -0.05.
The 52-week high of Twilight Litaka Phar is ₹2.88 and the 52-week low is ₹2.88.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Twilight Litaka Phar is ₹12.49 ( Cr.) .
Data is not available for this company.
No data found
No data found
About Twilight Litaka Pharma Ltd
Twilight Litaka Pharma Ltd., formerly Li Taka Pharmaceuticals Ltd. was originally incorporated as Li Taka Pharmaceuticals Pvt. Ltd., on January 18,1974 under the Companies Act, 1956. Thereafter the said company was converted into a Public Limited Company and a fresh Certificate of Incorporation was obtained on December 9, 1985. The company came out with a Public Issue during the year 1986 for expansion, upgradation of its manufacturing facilities.
The company manufactures drugs and formulations in the form of tablets, capsules, ointment and liquids. The company’s products cover the following major therapeutic segments:
- Analgesics - Anti Inflammatory
- Anti-Asthmatic
- Antibiotics
- Anti-bacterials
- Vitamins
- Haematinics
- Cardiovascular drugs
The company has well equipped, modern manufacturing testing and packaging facilities at all its plants viz. Pimpri, Vadgaon and Vasai. The Pimpri Plant has been approved by Dept. of Science and Technology, Government of India for its R & D facilities. The plants at Vadgaon and Pimpri have also been approved by the Pune University for laboratory use by its students pursuing the Doctorate Degrees.
The facilities at Pimpri and Vadgoan are as per the World Health Organisation guidelines and in conformity with Good Manufacturing Practices (GMP), enabling the company to register its products for exports in several countries all over the world.
The company also has a well established distribution network all over India (except in Delhi and Uttaranchal) with a customer base of over 1,00, 000 doctors for 120 formulations distributed through 1000 stockists. The domestic marketing personnel comprise of over 600 field force and is registered with several Central and State agencies to cater to the requirements of large hospitals, railways, ESIC, GMDs, Post and Telegraph Dept. city contractors, autonomous bodies and armed forces. The company’s business mix also includes an exclusive marketing arrangement with Cipla Ltd. for marketing of its brands across 10 states in the country.
Different divisions of the company:
TL Pharma has five divisions for Domestic Market
- TLPL division:This division is also known as the Mother Division as it has products that form Centrum, Nucleus & Zenith divisions. This division holds the promise of very high growth rate in the turnover. This division is ably manned by 225 field personnel.
- Nutra division :The company has entered the nutraceutical segment with an exclusive division focused on nutritional therapy. The division’s foremost brand is “CALM CREAM†– a nutritional supplement for skin useful in treatment of psoriases and eczema. The focus of this division is on nutraceutical products that are used as adjuvant and support therapy segments like COQ CARE, ARTHRICARE, LBM CARE which will improve the quality of life of the patients.
- Centrum Division:This division also focuses on servicing specialities like Gynecologists, Paediatricians, Physicians, Surgeons, Orthopaedic Surgeons, General Practitioners. This division has a range of life saving antibiotic injectables vital for use in surgeries & ICUs. Besides there is a range of products like Litacid, Temptal, Epixyl Expectorant & Litacold which provide excellent relief from day to day ailments. This division is ably manned by 400 field personnel.
- Nucleus divisions :In these two divisions, the focus is on segments like the physicians, general practitioners, orthopaedics, surgeons and paediatricians. Some of their strong brands include Cefilite, Seratid,O1B, Paranac, Toxolite, Antif. The division is ably supported by over 500 field force, 125 Managers and marketed throughout the country
- Zenith :This division focuses on servicing two specialities of medical practitioners viz. dermatologists and gynaecologists. The fraternity is presented with a range of products prescribed for their patients on a regular basis. This division is supported by 115 field personnel across India, in select towns.
Product range of the company includes:
- Anti-Inflammatory / Analgesics / Anti-Pyretics
- Antacids
- Anthelmintics
- Antibiotics
- Anti - Emetics
- Anti - Fungal
- Anti - Protozoals Amoebicides
- Calcium Supplements
- Coagulants
- Gynaecology
- Expectorants / Cold Preparations / Mucolytics
- Iron - Preparations Folic Acid
- ORS
- Vitamins
- Tranquilizers
- Topical Preparations
- Tonics
Milestones:
- In the year 1974 the company was incorporated as Li Taka Pharmaceuticals Pvt. Ltd
- In the year 1988 Litaka Laboratories Pvt.amalgamated with the company under approved Scheme of Amalgamation.
- In the year 1995 Pegasus Laboratories amalgamated with the company under approved Scheme of Amalgamation.
- The Marketing Division of Borachem Industries was taken over by the company in the year 1997-98.
- In the year 2000, Clover Pharmaceuticals Private. Amalgamated with the company under approved Scheme of Amalgamation
- Care Unipac Pvt. merged with the company in pursuance of the order passed by the Hon’ble Bombay High Court on 28th April, 2006.
- The Registrar of Companies, Pune issued a fresh certificate in the new name of the company i.e. Twilight Litaka Pharma Limited on 4th July, 2006
- On 20th October, 2006 the Hon’ble Bombay High Court passed an order confirming the Scheme of Reduction of Share Capital of the company.
You have 49 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
